ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in ARS Pharmaceuticals, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 92
- +3 vs. Q1 2023
- Shares held
- 55.1M
- +1.68M (+3.1%) vs. Q1 2023
- Total value
- $369.0M
- +$21.5M (+6.2%) vs. Q1 2023
- New holders
- 31
- 32 more added
- Sold out
- 28
- 19 more reduced
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SPRY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 208 | $726.0M |
| Q1 2026 | 203 | $757.5M |
| Q4 2025 | 191 | $1.05B |
| Q3 2025 | 188 | $840.4M |
| Q2 2025 | 188 | $1.48B |
| Q1 2025 | 184 | $958.9M |
| Q4 2024 | 166 | $752.3M |
| Q3 2024 | 151 | $928.4M |
| Q2 2024 | 115 | $533.0M |
| Q1 2024 | 113 | $612.1M |
| Q4 2023 | 100 | $358.5M |
| Q3 2023 | 97 | $251.6M |
| Q2 2023 | 92 | $369.0M |
| Q1 2023 | 90 | $347.7M |
| Q4 2022 | 73 | $427.9M |
| Q3 2022 | 61 | $160.4M |
| Q2 2022 | 64 | $110.5M |
| Q1 2022 | 70 | $94.7M |
| Q4 2021 | 72 | $200.5M |
| Q3 2021 | 74 | $288.4M |
| Q2 2021 | 76 | $864.6M |
| Q1 2021 | 68 | $1.21B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding ARS Pharmaceuticals, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Knollwood Investment Advisory, LLC | 0 | $0 | 0.00% | −32,174−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −24,302−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −23,869−100.0% | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −21,500−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −21,207−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −15,319−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −15,053−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −13,157−100.0% | Sold out |
| Nations Financial Group Inc, | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −10,744−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,411−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −7,476−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −5,238−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −5,011−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,903−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −243−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −240−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −117−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −45−100.0% | Sold out |
| ETF Managers Group, LLC | – | – | – | – | Not filed |